
treatment short stature children adolescents 
human pituitary growth hormone (raben).  experience 
thirty-five cases. 
human pituitary growth hormone (raben) 
evaluated longitudinal study 
growth therapeutic agent treatment 
short stature.  clinically significant 
increases growth rate achieved 11 
13 hypopituitary patients.  significant 
improvement linear growth rate 
noted dose 2 mg 3 times 
weekly children whose short stature due 
conditions.  adverse reactions 
noted; thyroidal, adrenal gonadal 
activation observed.  growth 
stimulated, probably without undue increase 
bone age, though point 
demands continued scrutiny.  owing limited 
supply material recommended 
used cases documented 
growth failure, protocol 
evaluation therapeutic response discussed. 
though panacea treatment 
short stature, human growth hormone 
fulfils unique invaluable role 
replacement therapy hypopituitary dwarf. 
